AbstractNo abstract available
Keywords: apomorphine; drug‐induced anemia; hemolytic anemia.
Bendamustine-induced Immune Hemolytic Anemia in a Chronic Lymphocytic Leukemia Patient: A Case Report and Review of the LiteratureH Haddad et al. Hematol Oncol Stem Cell Ther 7 (4), 162-4. PMID 24785506. - ReviewBendamustine is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. There are scant reports on bendamust …
Drug-induced Hemolytic Anemia: Pharmacological AspectsD Renard et al. Transfus Clin Biol 24 (3), 110-114. PMID 28648734. - ReviewDrug-induced hemolytic anemia is a very rare but potentially lethal adverse drug reaction, which can take the form of oxidative damage to vulnerable erythrocytes (as in g …
Ceftriaxone-induced Immune Hemolytic AnemiaG Neuman et al. Ann Pharmacother 48 (12), 1594-604. PMID 25163809. - Case ReportsGiven the common use of ceftriaxone worldwide, knowledge of CIIHA, which often goes undiagnosed until late in the course, is essential for clinicians. Based on the findin …
[Drug-induced Hemolytic Anemia]A Miura. Nihon Rinsho 54 (9), 2534-8. PMID 8890590. - ReviewAcquired drug-related hemolytic anemia is mainly induced by immune mechanism or microvascular lesion. Three mechanisms of drug-related immunologic injury to red blood cel …
The First Example of a Patient With Etoricoxib-Induced Immune Hemolytic AnemiaB Mayer et al. Transfusion 53 (5), 1033-6. PMID 22882551. - Case ReportsEtoricoxib should be considered as a risk in the development of immune hemolytic anemia, with the causative antibodies potentially reacting with other COX inhibitors.
Cited by 1 PubMed Central articles
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New FormulationsF Carbone et al. CNS Drugs 33 (9), 905-918. PMID 31473980. - ReviewSatisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may ex …